Emmanuel Caeymaex - UCB SA President
UCBJY Stock | USD 58.22 1.22 2.14% |
President
Mr. Emmanuel Caeymaex has served as Executive Vice President, Immunology Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 2015. He joined UCB in March 1994. He leads the understanding of patient needs, the development and commercialization of solutions which create value for people suffering from autoimmune disorders such as bowel diseases, skin conditions and lupus. Over the last 20 years Emmanuel was instrumental in advancing UCBs transformation into a global company focused on patients with severe diseases. Prior to this appointment he led the Cimzia Global Patient Solutions team. Emmanuel formerly served as President of UCB Japan Co Ltd. from September 2006 to June 2011 and on the Global Operations Committee. He previously contributed to build UCBs leadership position in epilepsy, successively as Global Brand Manager Keppra, UK Business Unit Head, and Vice President Global Marketing for Central Nervous System products. Prior to 1999, Emmanuel established and ran UCBs operations in several AsiaPacific markets for which he was awarded as Laureate of the Prince Albert Fund. He received a Business Engineer MS degree from Universite Catholique de Louvaine, Belgium, a Masters in International Management from the Global Alliance in Management Education and was continuing his executive leadership development journey at INSEAD. since 2015.
Age | 54 |
Tenure | 9 years |
Phone | 32 2 559 99 99 |
Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Daniel Plew | Regeneron Pharmaceuticals | 51 | |
Michael Aberman | Regeneron Pharmaceuticals | 45 | |
Jesper Brandgaard | Novo Nordisk AS | 54 | |
Reshma Kewalramani | Vertex Pharmaceuticals | 45 | |
Henrik Wulff | Novo Nordisk AS | 54 | |
Marion McCourt | Regeneron Pharmaceuticals | 64 | |
Tom Waldron | Pearson PLC ADR | N/A | |
Michael Parini | Vertex Pharmaceuticals | 43 | |
Karsten Knudsen | Novo Nordisk AS | 53 | |
Doug Langa | Novo Nordisk AS | 52 | |
Joseph LaRosa | Regeneron Pharmaceuticals | 65 | |
Christopher Fenimore | Regeneron Pharmaceuticals | 53 | |
Rod Bristow | Pearson PLC ADR | 62 | |
Charles Milstein | Vertex Pharmaceuticals | 42 | |
Douglas McCorkle | Regeneron Pharmaceuticals | 58 | |
Kasper Poulsen | Novo Nordisk AS | N/A | |
Ludovic Helfgott | Novo Nordisk AS | 50 | |
Douglas Langa | Novo Nordisk AS | 58 | |
Charles Wagner | Vertex Pharmaceuticals | 56 | |
Jeffrey Chodakewitz | Vertex Pharmaceuticals | 60 | |
Ian Smith | Vertex Pharmaceuticals | 51 |
Management Performance
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 |
UCB SA ADR Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
Detlef Thielgen, CFO and Executive VP | ||
Kay Davies, Independent Director | ||
Dirk Teuwen, VP Corporate Societal Responsibility | ||
Anna Richo, Executive VP and General Counsel | ||
Viviane Monges, Independent Non-Executive Director | ||
Gerhard Mayr, Non-Executive Chairman of the Board | ||
Cyril Janssen, Director | ||
Caroline Vancoillie, Chief Functions | ||
Cedric Rijckevorsel, Director | ||
JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
Arnoud Calesberg, Non-Executive Director | ||
Mark McDade, COO and Executive VP | ||
Xavier Michel, Vice President and Secretary General | ||
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
Norman Ornstein, Non-Executive Independent Director | ||
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
JeanPierre Kinet, Non-Executive Independent Director | ||
Antje Witte, VP of Investor Relations | ||
Alice Dautry, Independent Director | ||
Sandrine CFA, Ex CFO | ||
Harriet Edelman, Non-Executive Independent Director | ||
Ulf Wiinberg, Independent Director | ||
William Silbey, Exec Counsel | ||
Thomas McKillop, Non-Executive Independent Director | ||
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
France Nivelle, VP Global Communication | ||
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
Pierre Gurdjian, Independent Director | ||
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
CharlesAntoine Janssen, Non-Executive Director | ||
Pr LowFriedrich, Chief VP | ||
Kirsten LundJurgensen, Ex Solutions | ||
Albrecht Graeve, Non-Executive Independent Director | ||
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | 16.62 B | |||
Shares Outstanding | 379.92 M | |||
Price To Earning | 17.55 X | |||
Price To Book | 1.55 X | |||
Price To Sales | 2.54 X | |||
Revenue | 5.78 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ABBV | AbbVie Inc | |
HBI | Hanesbrands | |
MIDU | Direxion Daily Mid |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |